

In claim 34, line 4, replace "-H" with --OH-- and in line 19, replace "a" with --an N-containing--.

Please add the following new claims:

1 ~~--35.~~ (R)-bis(POC)PMPA.--

2 ~~--36.~~ A composition comprising (R)-bis(POC)PMPA and a pharmaceutically acceptable carrier.--

B' 3 ~~--37.~~ A method comprising orally administering to a patient infected with virus or at risk to viral infection a therapeutically effective amount of (R)-bis(POC)PMPA.--


Remarks

The specification and claims 33 and 34 have been amended to conform with changes made in the corresponding International Application. The change relating to Z makes the definition for this site in the 1a structure consistent with those found in structure (1) and the rest of the specification (which does not disclose H-phosphonates). With regard to the other editorial amendment, cyclization of the N-linked R groups will necessarily yield an N-containing heterocycle or N- and oxygen-containing heterocycle.

New claims 35-37 are directed to applicants' preferred embodiment. The basis for new claim 35 is at least page 45, line 15 or page 69, structure 5f. New claim 36 is based at least on specification page 39, line 15. New claim 37 is based at least on original claim 26. These three new claims all fall within the scope of the claims previously allowed in USSN 08/900,746.

An early action on the merits is solicited.

Respectfully submitted,



Max Hensley, Reg. No. 27,043
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404
Telephone: (650) 573-4878
Facsimile: (650) 573-4899
E-mail: Max_Hensley@Gilead.com

Date: 2-2-99